Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Digestion and Medical Imageology(Electronic Edition) ›› 2019, Vol. 09 ›› Issue (06): 256-262. doi: 10.3877/cma.j.issn.2095-2015.2019.06.005

Special Issue:

• Clinical Science Research • Previous Articles     Next Articles

Prevention for rebleeding of esophageal varices under the guidance of hepatic venous pressure gradient

Sining Wang1, Guangchuan Wang1, Mingyan Zhang1, Guangjun Huang1, Shiyao Chen2, Chunqing Zhang1,()   

  1. 1. Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
    2. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Received:2019-10-03 Online:2019-12-01 Published:2019-12-01
  • Contact: Chunqing Zhang
  • About author:
    Corresponding author: Zhang Chunqing, Email:

Abstract:

Objective

Hepatic venous pressure gradient(HVPG)is an important indicator for the evaluation and prognosis of liver cirrhosis.This study explores the value of different procedures according to HVPG for reducing the rate of rebleeding in cirrhotic patients with esophageal varices.

Methods

A total of 270 cirrhotic patients with esophageal varices who had a history of variceal bleeding and HVPG performance from April 2010 to October 2019 were enrolled.Among them, 130 patients(HVPG guided group)underwent individualized treatment according to HVPG value: patients with 10 mmHg≤HVPG≤16 mmHg accepted endoscopic esophageal variceal ligation(EVL)combined with non-selectiveβreceptor blocker(NSBB)treatment; patients with 16 mmHg<HVPG≤20 mmHg underwent percutaneous transhepatic variceal embolization (PTVE); for patients with HVPG>20 mmHg, transjugular intrahepatic portosystemic shunt(TIPS)was used.Another 140 patients(non-HVPG guided group)were treated with EVL plus NSBB.The primary end point was rebleeding associated with portal hypertension, and the secondary end point was death.

Results

The median follow-up time was 26 months.The rate of rebleeding in the HVPG guided group was lower than that in the non-HVPG guided group(12.31% vs.30.00%, P=0.000 88), but there was no significant difference in survival between the two groups(93.08% vs.91.43%, P=0.71). Further subgroup analysis showed that for patients with 16 mmHg<HVPG≤20 mmHg, the rebleeding rate of patients with PTVE treatment was lower than that of patients with EVL+ NSBB(5.00% vs.31.82%, P=0.02), but there was no significant difference in survival between the two groups.In patients with HVPG>20 mmHg, the rebleeding rate of patients with TIPS was lower than that of patients with EVL+ NSBB(6.12% vs.36.36%, P=0.000 88), but there was no significant difference in survival between the two groups.

Conclusion

Individualized therapy based on HVPG has important theoretical and clinical significance.According to the risk stratification of HVPG, individualized choice of secondary prevention of esophageal variceal bleeding(EVL+ NSBB, PTVE or TIPS)can reduce the risk of rebleeding, which is worthy of further clinical research for individualized therapy of cirrhotic patients.

Key words: Liver cirrhosis, Individualized treatment, Hepatic vein pressure gradient, Percutaneous transhepatic variceal embolization, Transjugular intrahepatic portosystemic shunt

京ICP 备07035254号-15
Copyright © Chinese Journal of Digestion and Medical Imageology(Electronic Edition), All Rights Reserved.
Tel: 0531-83086377 15564155687 E-mail: zhxhbyyxzz@126.com
Powered by Beijing Magtech Co. Ltd